INSERM U775, Centre Universitaire des Saints Pères, Paris, France ; Service de Biochimie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France ; Service de Néphrologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France ; Université Paris Descartes, Paris, France.
Service de Néphrologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France ; Université Paris Descartes, Paris, France.
PLoS One. 2014 Jan 8;9(1):e84708. doi: 10.1371/journal.pone.0084708. eCollection 2014.
Currently, a non-invasive method to estimate the degree of interstitial fibrosis (IF) in chronic kidney disease is not available in routine. The aim of our study was to evaluate the diagnostic performance of the measurement of urinary low molecular weight (LMW) protein concentrations as a method to determine the extent of IF. The urines specimen from 162 consecutive patients who underwent renal biopsy were used in the analysis. Numerical quantification software based on the colorimetric analysis of fibrous areas was used to assess the percentage IF. Total proteinuria, albuminuria, and the urinary levels of retinol binding protein (RBP), alpha1-microglobulin (α1MG), beta 2-microglobulin (β2MG), transferrin, and IgG immunoglobulins were measured. There was a significant correlation between the degree of IF and the RBP/creatinine (creat) ratio (R2: 0.11, p<0.0001). IF was associated to a lesser extent with urinary β2MG and α1MG; however, there was no association with total proteinuria or high molecular weight (HMW) proteinuria. The correlation between IF and RBP/creat remained significant after adjustment to the estimated glomerular filtration rate, age, body mass index, α1MG, and β2MG. The specificity of the test for diagnosing a fibrosis score of >25% of the parenchyma was 95% when using a threshold of 20 mg/g creat. In conclusion, RBP appears to be a quantitative and non-invasive marker for the independent prediction of the extent of kidney IF. Because methods for the measurement of urinary RBP are available in most clinical chemistry departments, RBP measurement is appealing for implementation in the routine care of patients with chronic kidney disease.
目前,在常规情况下,还没有一种非侵入性的方法来评估慢性肾脏病间质纤维化(IF)的程度。我们的研究目的是评估测量尿低分子量(LMW)蛋白浓度作为一种确定 IF 程度的方法的诊断性能。分析中使用了 162 例连续接受肾活检的患者的尿液标本。基于纤维区域比色分析的数值量化软件用于评估 IF 的百分比。测量总蛋白尿、白蛋白尿以及尿视黄醇结合蛋白(RBP)、α1-微球蛋白(α1MG)、β2-微球蛋白(β2MG)、转铁蛋白和 IgG 免疫球蛋白的水平。IF 程度与 RBP/肌酐(creat)比值呈显著相关(R2:0.11,p<0.0001)。IF 与尿β2MG 和 α1MG 相关性较小,但与总蛋白尿或高分子量(HMW)蛋白尿无关。在调整估计肾小球滤过率、年龄、体重指数、α1MG 和 β2MG 后,IF 与 RBP/creat 的相关性仍然显著。当使用 20mg/g creat 的阈值时,该检测用于诊断 25%以上实质纤维化评分的特异性为 95%。总之,RBP 似乎是预测肾脏 IF 程度的一种定量、非侵入性的标志物。由于大多数临床化学部门都可以测量尿 RBP,因此 RBP 测量对于实施慢性肾脏病患者的常规护理具有吸引力。